Patent ID: 8758753

Claim:
A humanized monoclonal antibody derived from murine anti-idiotypic monoclonal antibody 1E10, said murine anti-idiotypic monoclonal antibody 1E10 being produced by an hybridoma cell line with deposit number ECACC 97112901 and recognizing monoclonal antibody P3 (“Mab P3”), said Mab P3 being produced by hybridoma cell line with deposit number ECACC 94113026, wherein said humanized monoclonal antibody derived from murine anti-idiotypic monoclonal antibody 1E10 comprises: (a) a heavy chain constant region of human gamma-1 chain; (b) a light chain constant region of human kappa chain; (c) heavy chain variable region hypervariable domains (CDRs) comprising the following sequences: CDR1: SYDIN (SEQ ID NO: 15); CDR2: WIFPGDGSTKYNEKFKG (SEQ ID NO: 16); CDR3: EDYYDNSYYFDY (SEQ ID NO: 17); (d) light chain variable region CDRs comprising the following sequences: CDR1: RASQDISNYLN (SEQ ID NO: 18); CDR2: YTSRLHSG (SEQ ID NO: 19); CDR3: QQGNTLPWT (SEQ ID NO: 20); (e) heavy chain variable region framework regions (FRs) comprising the following sequences: FR1: QVQLQQSGAELVKPGASVKLSCKASGYTFT (SEQ ID NO: 21); FR2: WVRQRPEQGLEWIG (SEQ ID NO: 22); FR3: KATLTTDKSSSTAYMQLSRLTSEDSAVYFCAR (SEQ ID NO: 23); FR4: WGQGTTLTV (SEQ ID NO: 24); (f) light chain variable region FRs comprising the following sequences: FR1: DIQMTQTTSSLSASLGDRVTISC (SEQ ID NO: 25); FR2: WYQQKPDGTVKLLIY (SEQ ID NO: 26); FR3: VPSRFSGSGSGTDYSLTISNLEQEDIATYFC (SEQ ID NO: 27); FR4: FGGGTKLESK (SEQ ID NO: 28); and (g) further comprising at least one of the following substitutions in the FRs: LIGHT CHAIN variable region FRs: Position 7 in SEQ ID NO: 25: Thr by Ser; Position 8 in SEQ ID NO: 25: Thr by Pro; Position 15 in SEQ ID NO: 25: Leu by Val; HEAVY CHAIN variable region FRs: Position 5 in SEQ ID NO: 21: Gln by Val; Position 5 in SEQ ID NO: 22: Arg by Ala; Position 7 in SEQ ID NO: 22: Glu by Gly; Position 21 in SEQ ID NO: 23: Thr by Arg.